- More amenable to use in children and the elderly
- Cross protective, valuable for seasonal changes in influenza and valuable for pandemics
- More effective vaccines, for example for TB
- More boostable immune responses
- Lower dose is required, reducing costs and time of manufacture, and facilitating storage and logistics issues etc.
- No lag time to bank feedstocks & manufacture vaccine lots